CLINICAL_TRIALS
trial_result
· 2021-07-29
Clinical Trial Update: Safety And Efficacy Evaluation Of Fx-1006A In Subjects With Transthyretin Amyloidosis [Phase 3]
Summary
Phase 3 trial evaluating safety and efficacy of Fx-1006A in transthyretin amyloidosis with polyneuropathy (ATTR-PN) has completed.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Pfizer | Conditions: ATTR-PN | Phase 3 | Status: COMPLETED | Results posted: 2021-07-29